Industry News
Pharmaceutical Industry News
Thursday evening, President Donald…
Thursday evening, President Donald Trump debuted TrumpRx, a government-run website that directs patients toward cash-pay channels where they can purchase certain prescription drugs.
A month after drugmaker Novo…
A month after drugmaker Novo Nordisk launched its Wegovy pill, online health and wellness company Hims & Hers plans to undercut it with a compounded semaglutide pill offered at a lower price.
The majority of Bristol Myers…
The majority of Bristol Myers Squibb's $48.2 billion revenue haul in 2025 came from its collection of newer growth products as its legacy portfolio declines.
Astellas surpassed market…
Astellas surpassed market expectations in its third-quarter fiscal year 2025 results, as first-in-class cancer drug Vyloy defied a trial setback to deliver quadrupled sales.
In its initial public offering,…
In its initial public offering, Veradermics sold a little over 15 million shares of common stock at $17 apiece, raising a total of $256.3 million in its entry onto the New York Stock Exchange, according
Merz Therapeutics has launched a…
Merz Therapeutics has launched a punchy marketing campaign for Parkinson’s disease drug Inbrija, working Muhammad Ali quotes and footage into a revised version of the med’s “For the Fighters” initiative.
F.T.C. Settles With Express Scripts Over High Insulin Prices
The Trump administration announced that the company, a pharmacy benefit manager, had agreed to make significant changes to its practices.
Novo Nordisk Warns of First Sales Drop Since Start of Ozempic
The once high-flying Danish drugmaker has struggled to fend off rivals in the weight-loss industry, especially Eli Lilly, which gave a much rosier outlook to investors.
By signing a government funding…
By signing a government funding bill that ended a partial shutdown, President Donald Trump has also reauthorized a beloved program meant to speed the development of new drugs for rare childhood diseases.
For Sun Pharma, every day—from…
For Sun Pharma, every day—from Super Bowl Sunday and beyond—is “SUNday.”
Eli Lilly said it will be impacted…
Eli Lilly said it will be impacted by pricing pressures in 2026 for its juggernaut products Mounjaro and Zepbound. But the company's momentum is such that it still expects revenues to reach between $80 billion
AbbVie’s immunology drug portfolio…
AbbVie's immunology drug portfolio of Skyrizi, Rinvoq and older Humira contributed $30.4 billion to the company's yearly haul of $61.1 billion.
Novartis CEO Vas Narasimhan is…
Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s fourth-quarter results start to show the impact of the “largest patent expiry” in its history.
Bristol Myers Squibb has signed…
Bristol Myers Squibb has signed Kasey Keller for a Breyanzi partnership, giving the U.S, Soccer Hall of Famer a platform to discuss how the CD19-directed CAR-T cell therapy blocked the recurrence of his non-Hodgkin lymphoma.
Congress Reins In Drug Middlemen in Effort to Lower Prescription Prices
The legislation will impose new restrictions on pharmacy benefit managers, giant companies like CVS Caremark, Optum Rx and Express Scripts that oversee prescription drug benefits.
OXB, a U.K.-based cell and gene…
OXB, a U.K.-based cell and gene therapy manufacturer, expanded its ongoing partnership with Bristol Myers Squibb to supply lentiviral vectors for the pharma giant’s CAR-T programs.
In his first investor update as…
In his first investor update as GSK’s CEO, Luke Miels defined a core of his vision for the company’s next chapter: “We need to be more product-centric as a company.”
Amgen has denied a request by the…
Amgen has denied a request by the FDA to voluntarily withdraw its rare disease drug Tavneos from the market, the company said Tuesday as it presented quarterly financial results.
Vice and the Crisis of Liberalism
Is there a political prescription for our era of addiction?
Long known for manufacturing…
Long known for manufacturing generics, vaccines and small-molecule drugs, India is attempting to shift its focus, with a big boost from its government. The country will invest 100 billion rupees ($1.1 billion) over the next